- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Hypotrophy.
Displaying page 1 of 1.
| EudraCT Number: 2008-006379-65 | Sponsor Protocol Number: 02A801 | Start Date*: 2008-10-27 |
| Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO | ||
| Full Title: Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease | ||
| Medical condition: sperimentation only in patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004696-12 | Sponsor Protocol Number: FACIALPARALYSIS | Start Date*: 2020-01-15 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
| Full Title: Clinical, Instrumental and Histological evaluation of the combined use of Onabotulinumtoxin A and hyaluronic acid fillers in patients with facial paralysis | |||||||||||||
| Medical condition: hemifacial paralysis (3 to 6 of the House-Brackmann scale) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004866-86 | Sponsor Protocol Number: P160944J | Start Date*: 2020-01-23 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
| Full Title: Evaluation of the benefit of adjuvant treatment with hydroxychloroquine to usual medical care for uncomplicated term pregnancy in patients with primary obstetrical antiphospholipid syndrome: random... | |||||||||||||
| Medical condition: Primary obstetrical antiphospholipid syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-002827-14 | Sponsor Protocol Number: TreatSPG11 | Start Date*: 2021-01-19 | |||||||||||
| Sponsor Name:IRCCS Fondazione Stella Maris | |||||||||||||
| Full Title: Phase 2 pharmacological experimental study to test the safety of miglustat in subjects with hereditary spastic paraplegia type 11 | |||||||||||||
| Medical condition: Spastic paraparesis type 11 (SPG11), caused by mutations in spatacsin protein, is characterized by the association of peripheral neuropathy, parkinsonism, ataxia, cognitive impairment, hypotrophy o... | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.